论文部分内容阅读
目的探讨IFN -α对慢性乙型病毒肝炎抗肝纤维化的治疗作用。方法 :血清TGFβ1检测采用酶联免疫吸附试验法 ,HA、LN和PCⅢ测定均采用放射免疫法。结果 :治疗前两组患者的血清TGFβ1、HA、LN和PCⅢ无显著性差异 (P >0 .0 5 ) ,治疗组在治疗后TGFβ1、HA、LN和PCⅢ都比治疗前有明显下降 (P <0 .0 1) ,而对照组治疗前后统计学无意义 (P >0 .0 5 )。且HBeAg转阴率与对照组比较有显著性差异 (P <0 .0 5 )。结论 :IFN -α具有一定的抗肝纤维化作用。
Objective To investigate the therapeutic effect of IFN-α on hepatic fibrosis induced by chronic hepatitis B virus. Methods: Serum TGFβ1 was detected by enzyme-linked immunosorbent assay (ELISA). The radioimmunoassay was used to determine the levels of HA, LN and PCⅢ. Results: The serum levels of TGFβ1, HA, LN and PCⅢ in the two groups before treatment were not significantly different (P> 0.05), and the levels of TGFβ1, HA, LN and PCⅢ in the treatment group were significantly decreased after treatment <0.01), while the control group was statistically insignificant before and after treatment (P> 0.05). The negative rate of HBeAg in the control group was significantly different (P <0.05). Conclusion: IFN-α has some anti-hepatic fibrosis effect.